KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Other Accumulated Expenses (2019 - 2023)

Historic Other Accumulated Expenses for GoodRx Holdings (GDRX) over the last 5 years, with Q1 2023 value amounting to $8.5 million.

  • GoodRx Holdings' Other Accumulated Expenses rose 7735.89% to $8.5 million in Q1 2023 from the same period last year, while for Mar 2023 it was $8.5 million, marking a year-over-year increase of 7735.89%. This contributed to the annual value of $6.9 million for FY2022, which is 5897.67% up from last year.
  • As of Q1 2023, GoodRx Holdings' Other Accumulated Expenses stood at $8.5 million, which was up 7735.89% from $6.9 million recorded in Q4 2022.
  • GoodRx Holdings' 5-year Other Accumulated Expenses high stood at $11.4 million for Q3 2022, and its period low was $1.9 million during Q4 2019.
  • For the 5-year period, GoodRx Holdings' Other Accumulated Expenses averaged around $5.9 million, with its median value being $5.2 million (2021).
  • Per our database at Business Quant, GoodRx Holdings' Other Accumulated Expenses soared by 27891.41% in 2020 and then tumbled by 3963.55% in 2021.
  • Quarter analysis of 5 years shows GoodRx Holdings' Other Accumulated Expenses stood at $1.9 million in 2019, then surged by 278.91% to $7.2 million in 2020, then plummeted by 39.64% to $4.3 million in 2021, then soared by 58.98% to $6.9 million in 2022, then increased by 23.44% to $8.5 million in 2023.
  • Its Other Accumulated Expenses stands at $8.5 million for Q1 2023, versus $6.9 million for Q4 2022 and $11.4 million for Q3 2022.